RCM
BBIO icon

Riverhead Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Riverhead Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$25K Buy
+1,183
New +$32.7K ﹤0.01% 1462

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Riverhead Capital Management's BBIO Position: Q3 2019 in Review

Riverhead Capital Management opened a new position in BridgeBio Pharma (BBIO) in Q3 2019: 1,183 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #1462 among its holdings.

75 funds tracked by Wall St. Rank hold BBIO as of Q3 2019.

  • Riverhead Capital Management held 1,183 shares of BridgeBio Pharma worth $25K as of Q3 2019.
  • BridgeBio Pharma was a new Riverhead Capital Management position in Q3 2019.
  • BridgeBio Pharma made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1462 holding.
  • 75 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.